ArticleScience advances2026
Accelerated discovery of cell migration regulators using label-free deep learning-based automated tracking.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Cell migration underlies immune surveillance, tissue repair, embryogenesis, and-when dysregulated-tumor metastasis. Yet unlike proliferation, which can be profiled at scale, migration studies remain limited by labor-intensive imaging and analysis. Existing assays often forfeit single-cell resolution, require phototoxic fluorescent labeling, or depend on tedious manual tracking, restricting the range of molecular perturbations and microenvironmental contexts that can be examined. We present Deep learning Brightfield Imaging and cell Tracking (DeepBIT), a high-throughput platform that captures live-cell behavior in multiwell plates and uses a convolutional neural network to detect and track individual cells in brightfield videos-without labels or user bias. Brightfield images are paired with nuclear fluorescence images to generate diverse ground-truth datasets, enabling automated training and eliminating manual annotation. This scalability supports a data-driven approach to systematically dissect the regulation of cell migration. Using breast cancer cells as a testbed, we tracked ~1500 cells per well across 840 conditions-including 96 FDA-approved drugs at multiple doses, a range of extracellular matrix and growth factor combinations, and CRISPR knockouts of cytoskeletal genes-yielding ~1.3 million trajectories in 30 hours (~2 minutes per condition). This dataset revealed previously unrecognized motility modulators among FDA-approved compounds and uncovered strong context dependence; for example, TNF-α and RhoA could either suppress or promote migration in the same cells depending on extracellular cues. Together, DeepBIT provides an unbiased, label-free platform for single-cell motility profiling at a scale compatible with modern drug libraries and genomic perturbation tools, enabling systematic exploration and therapeutic targeting of cell migration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.